Press releases
- PTC Therapeutics to Participate at Upcoming Investor Conference
- PTC Therapeutics Announces Validation of Sepiapterin European MAA
- PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation
- PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
- PTC Therapeutics to Participate at Upcoming Investor Conferences
- PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
- PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
- PTC Therapeutics Provides Key Regulatory Updates
More ▼
Key statistics
On Friday, PTC Therapeutics Inc (BH3:FRA) closed at 32.60, -21.26% below its 52-week high of 41.40, set on Jun 07, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.60 |
---|---|
High | 32.60 |
Low | 32.60 |
Bid | 32.80 |
Offer | 34.20 |
Previous close | 31.80 |
Average volume | 0.00 |
---|---|
Shares outstanding | 76.70m |
Free float | 74.84m |
P/E (TTM) | -- |
Market cap | 2.79bn USD |
EPS (TTM) | -7.69 USD |
Data delayed at least 15 minutes, as of May 31 2024 07:14 BST.
More ▼